- Home
- ANAB vs MGTX Comparison
ANAB vs MGTX Comparison
Compare ANAB & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- MGTX
- Stock Information
- Founded
- ANAB 2005
- MGTX 2015
- Country
- ANAB United States
- MGTX United States
- Employees
- ANAB N/A
- MGTX N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANAB Health Care
- MGTX Health Care
- Exchange
- ANAB Nasdaq
- MGTX Nasdaq
- Market Cap
- ANAB 621.1M
- MGTX 670.2M
- IPO Year
- ANAB 2017
- MGTX N/A
- Fundamental
- Price
- ANAB $20.14
- MGTX $8.17
- Analyst Decision
- ANAB Buy
- MGTX Strong Buy
- Analyst Count
- ANAB 10
- MGTX 2
- Target Price
- ANAB $48.00
- MGTX $24.00
- AVG Volume (30 Days)
- ANAB 500.2K
- MGTX 545.7K
- Earning Date
- ANAB 08-06-2025
- MGTX 08-14-2025
- Dividend Yield
- ANAB N/A
- MGTX N/A
- EPS Growth
- ANAB N/A
- MGTX N/A
- EPS
- ANAB N/A
- MGTX N/A
- Revenue
- ANAB $123,164,000.00
- MGTX $37,917,000.00
- Revenue This Year
- ANAB N/A
- MGTX $228.65
- Revenue Next Year
- ANAB $24.39
- MGTX $145.06
- P/E Ratio
- ANAB N/A
- MGTX N/A
- Revenue Growth
- ANAB 304.17
- MGTX 366.84
- 52 Week Low
- ANAB $12.21
- MGTX $3.85
- 52 Week High
- ANAB $40.70
- MGTX $8.98
- Technical
- Relative Strength Index (RSI)
- ANAB 31.39
- MGTX 55.70
- Support Level
- ANAB $19.55
- MGTX $7.53
- Resistance Level
- ANAB $22.03
- MGTX $8.63
- Average True Range (ATR)
- ANAB 1.50
- MGTX 0.47
- MACD
- ANAB -0.53
- MGTX -0.02
- Stochastic Oscillator
- ANAB 12.05
- MGTX 66.17
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.